The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials
Open Access
- 28 August 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 97 (5), 577-581
- https://doi.org/10.1038/sj.bjc.6603925
Abstract
An increase in the number of identified therapeutic cancer targets achieved through recent biomedical research has resulted in the generation of a large number of molecules that need to be tested further. Current development of (anticancer) drugs is a rather inefficient process that for an average new molecule takes around 10–15 years. It is also a challenging process as it is associated with high costs and a low rate of approval. It is known that less than 10% of new molecular entities entering clinical Phase I testing progress beyond the investigational programme and reach the market; this probability is even lower for anticancer agents. In 2003, the US Food and Drug Administration (US FDA) declared the urgent need for new toolkits to improve the critical development path that leads from scientific discovery to the patient. In this scenario, Phase 0 (zero) trials should allow an early evaluation in humans of pharmacokinetic and pharmacodynamic profiles of test compounds through administration of sub-pharmacological doses and for a short time period to a low number of humans. Typically, Phase 0 studies have no therapeutic or diagnostic intent. Owing to the low doses administered and the low risk of toxicity, shorter preclinical packages to support these studies are required. Phase 0 trials have been proposed to help in making an early selection of promising candidates for further evaluation in Phase I–III trials, providing a potentially useful instrument for drug discovery, particularly in the field of oncology. Phase 0 studies are expected to reduce costs of drug development, and to limit the preclinical in vitro and in vivo testing and the time period of drug development. However, there are also concerns about the utility and feasibility of Phase 0 studies. In January 2006, guidelines on exploratory investigational new drug studies in humans have been published by the US FDA, and currently a Phase 0 programme is ongoing at the National Cancer Institute to evaluate the impact (feasibility and utility) of Phase 0 studies on drug development. In Europe, a Position Paper produced by the Evaluation of Medicinal Products (EMEA) in 2004 raised the possibility of a reduced preclinical safety package to support early microdose clinical studies, and, as announced by a recent Concept Paper on medicinal products published by the committee for medicinal products for human use of the EMEA, EMEA's guidelines on Phase 0 studies are expected shortly. The true impact of Phase 0 studies on the drug development process as well as on the safety needs to be carefully explored.Keywords
This publication has 17 references indexed in Scilit:
- Compressing drug development timelines in oncology using phase '0' trialsNature Reviews Cancer, 2007
- Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugsCancer Cell, 2006
- Minimally Invasive Pharmacokinetic and Pharmacodynamic Technologies in Hypothesis-Testing Clinical Trials of Innovative TherapiesJNCI Journal of the National Cancer Institute, 2006
- Preclinical Pharmacokinetics: An Approach Towards Safer and Efficacious DrugsCurrent Drug Metabolism, 2006
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- PET for in vivo pharmacokinetic and pharmacodynamic measurementsEuropean Journal Of Cancer, 2002
- Clinical Trial Design for Target-Based TherapyThe Oncologist, 2002
- The Value of Improving the Productivity of the Drug Development ProcessPharmacoEconomics, 2002
- Risks in new drug development: Approval success rates for investigational drugsClinical Pharmacology & Therapeutics, 2001
- Combinatorial chemistry in cancer drug development.2001